High-Dose vs Standard-Dose Ivermectin with Permethrin Cream for Scabies Treatment
|
Reviewed & Translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on May 25th, 2026
|
Scabies is a parasitic skin infection caused by the mite Sarcoptes scabiei. The infestation is particularly common in crowded communities with poor sanitation infrastructure. In severe cases, especially among immunocompromised individuals, scabies can lead to secondary bacterial infections, tissue necrosis, and even death. Although clinical evidence remains limited, many treatment guidelines recommend combining topical permethrin with oral ivermectin. A recent study published in the New England Journal of Medicine evaluated the effectiveness of this treatment strategy and examined whether a higher dose of ivermectin could improve clinical outcomes.
Funding Source(s): French Ministry of Health and French Society of Dermatology
The clinical trial included 132 participants with an average age of approximately 67 years who had been diagnosed with scabies. Around 60% of the patients had the profuse form of the disease, characterized by widespread erythematous and scaly skin lesions. Approximately 5% had crusted scabies, which is associated with hyperkeratotic and psoriasis-like lesions, while the remaining participants exhibited overlapping features of both forms. On days 1 and 7 of the study, all participants were treated with 5% permethrin cream applied from head to toe and left on overnight for at least 8 hours. Daily emollient therapy was also provided.
Participants were randomly assigned to receive oral ivermectin at either the standard dose of 200 micrograms per kilogram of body weight or a higher dose of 400 micrograms per kilogram. The medication was administered once every 7 days for a total of three doses. High-dose ivermectin has previously demonstrated effectiveness against other parasitic infections, including head lice and malaria. The drug acts by inhibiting glutamate-gated chloride channels found in parasites and helminths, leading to paralysis and death of the organism.
28 days after treatment initiation, the researchers found no significant difference in clinical outcomes between the high-dose and standard-dose ivermectin groups. Using the absence of active skin lesions as the definition of cure, both regimens achieved cure rates of approximately 80% when combined with permethrin cream. The researchers suggested that ivermectin may be less effective against scabies mites because, unlike blood-feeding parasites, Sarcoptes scabiei primarily feeds on intercellular fluid rather than blood, potentially limiting drug exposure despite adequate plasma concentrations. Previous studies have also suggested that permethrin monotherapy may be more effective than ivermectin alone. The authors emphasized the need for further studies to clarify the added benefit of ivermectin and to evaluate alternative topical scabicides such as benzyl benzoate emulsion and 1% lindane cream, particularly as resistance to permethrin continues to emerge.
Funding Source(s): French Ministry of Health and French Society of Dermatology
The clinical trial included 132 participants with an average age of approximately 67 years who had been diagnosed with scabies. Around 60% of the patients had the profuse form of the disease, characterized by widespread erythematous and scaly skin lesions. Approximately 5% had crusted scabies, which is associated with hyperkeratotic and psoriasis-like lesions, while the remaining participants exhibited overlapping features of both forms. On days 1 and 7 of the study, all participants were treated with 5% permethrin cream applied from head to toe and left on overnight for at least 8 hours. Daily emollient therapy was also provided.
Participants were randomly assigned to receive oral ivermectin at either the standard dose of 200 micrograms per kilogram of body weight or a higher dose of 400 micrograms per kilogram. The medication was administered once every 7 days for a total of three doses. High-dose ivermectin has previously demonstrated effectiveness against other parasitic infections, including head lice and malaria. The drug acts by inhibiting glutamate-gated chloride channels found in parasites and helminths, leading to paralysis and death of the organism.
28 days after treatment initiation, the researchers found no significant difference in clinical outcomes between the high-dose and standard-dose ivermectin groups. Using the absence of active skin lesions as the definition of cure, both regimens achieved cure rates of approximately 80% when combined with permethrin cream. The researchers suggested that ivermectin may be less effective against scabies mites because, unlike blood-feeding parasites, Sarcoptes scabiei primarily feeds on intercellular fluid rather than blood, potentially limiting drug exposure despite adequate plasma concentrations. Previous studies have also suggested that permethrin monotherapy may be more effective than ivermectin alone. The authors emphasized the need for further studies to clarify the added benefit of ivermectin and to evaluate alternative topical scabicides such as benzyl benzoate emulsion and 1% lindane cream, particularly as resistance to permethrin continues to emerge.